Statement Of Support By The PAP Foundation, Inc. For FDA Approval Of GM-CSF Treatment For aPAP
Savara, Inc. (SVRA)
Last savara, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
savarapharma.com/investors/events-presentations
Company Research
Source: PR Web
LOS ANGELES (PRWEB) March 25, 2020 The PAP Foundation, Inc. ("PAPF") is the primary patient advocacy organization for Pulmonary Alveolar Proteinosis ("PAP") in the United States and consists of clinicians, scientists, PAP patients and their family members. With foundational goals of finding a cure and improving the lives of those affected by PAP, we have received numerous testimonials from patients whose lives have significantly improved through the use of inhaled GM-CSF. Outcomes have included improvement in exercise tolerance and quality of life, decreased need for whole lung lavage, and decreased need for oxygen therapy. Moreover, we have witnessed patients who have discontinued GM-CSF therapy after seeing significant improvement only to suffer disease recurrence necessitating the resumption of GM-CSF treatment.PAPF commends both the PAGE (sponsored by Niigata University Medical & Dental Hospital) (shortened link: https://bit.ly/2WGi07F) and the IMPALA (sponsored by Savara Inc.)
Show less
Read more
Impact Snapshot
Event Time:
SVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SVRA alerts
High impacting Savara, Inc. news events
Weekly update
A roundup of the hottest topics
SVRA
News
- Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.MarketBeat
- Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 [Yahoo! Finance]Yahoo! Finance
- Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024Business Wire
- Savara Announces New Employment Inducement GrantBusiness Wire
- Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
SVRA
Earnings
- 11/9/23 - Miss
SVRA
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- SVRA's page on the SEC website